Loading…

Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non–Small-Cell Lung Cancer

Micro-Abstract Patients with non–small-cell lung cancer (NSCLC) often have bone metastases (BMs) in the late stage of disease. One hundred eighty patients with NSCLC were selected and treated with zoledronic acid (ZA) and/or strontium-89 (Sr-89). Combined therapy with ZA and Sr-89 is of clinical sig...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical lung cancer 2013-05, Vol.14 (3), p.254-260
Main Authors:	Wang, Yaopeng, Tao, Hao, Yu, Xuyi, Wang, Zhan, Wang, Mingzhao
Format:	Article
Language:	English
Subjects:	Adult Aged Bone Density Conservation Agents - therapeutic use Bone metastases Bone Neoplasms - drug therapy Bone Neoplasms - mortality Bone Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Diphosphonates - therapeutic use Double-Blind Method Female Fractures, Bone - prevention & control Hematology, Oncology and Palliative Medicine Humans Hypercalcemia - prevention & control Imidazoles - therapeutic use Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Non–small-cell lung cancer Paraneoplastic Syndromes - prevention & control Pulmonary/Respiratory Skeletal-related event Spinal Cord Compression - prevention & control Strontium - therapeutic use Strontium-89 Zoledronic acid
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3
cites	cdi_FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3
container_end_page	260
container_issue	3
container_start_page	254
container_title	Clinical lung cancer
container_volume	14
creator	Wang, Yaopeng Tao, Hao Yu, Xuyi Wang, Zhan Wang, Mingzhao
description	Micro-Abstract Patients with non–small-cell lung cancer (NSCLC) often have bone metastases (BMs) in the late stage of disease. One hundred eighty patients with NSCLC were selected and treated with zoledronic acid (ZA) and/or strontium-89 (Sr-89). Combined therapy with ZA and Sr-89 is of clinical significance for patients with NSCLC with asymptomatic BMs.
doi_str_mv	10.1016/j.cllc.2012.09.001
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1325329837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1525730412001982</els_id><sourcerecordid>1325329837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3</originalsourceid><addsrcrecordid>eNp9UsuqFDEQbUTxXq_-gAvJ0k23laS7pwMijI0vGB8wiuAmZPK4ZkwnY5IWZufWtX_ol5hmRhcuJIEUlXNOJXWqqu5jaDDg_tG-kc7JhgAmDbAGAN-oLjGjQw09g5sl7khXryi0F9WdlPYApKeY3K4uCMVAaUcuqx-js95K4dDWXntrSuilRsGgT8FpFUO5RGtpFRJeoW0uiWznqR4Ysh69E9lqnxP6aPNntE7H6ZDDVJISPQ1eo9c6i1S2TsjEMKE3wf_6_nM7CefqUTuHNrO_RuNSMt6tbhnhkr53Pq-qD8-fvR9f1pu3L16N600tW4xzbSgwNvSdaDswlKgdbamU3WroiQEhwaidIQNmQyuIYF1B4Z1UK6PKogIrelU9POkeYvg665T5ZJMsjxFehzlxTElHCRvoqkDJCSpjSClqww_RTiIeOQa-WMD3fLGALxZwYLxYUEgPzvrzbtLqL-VPzwvg8Qmgyy-_WR15kqWLUisbtcxcBft__Sf_0OXZwi_6qNM-zNGX_nHMU-Hw7TIEywxgUthsIPQ3gPGuKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1325329837</pqid></control><display><type>article</type><title>Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non–Small-Cell Lung Cancer</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Wang, Yaopeng ; Tao, Hao ; Yu, Xuyi ; Wang, Zhan ; Wang, Mingzhao</creator><creatorcontrib>Wang, Yaopeng ; Tao, Hao ; Yu, Xuyi ; Wang, Zhan ; Wang, Mingzhao</creatorcontrib><description>Micro-Abstract Patients with non–small-cell lung cancer (NSCLC) often have bone metastases (BMs) in the late stage of disease. One hundred eighty patients with NSCLC were selected and treated with zoledronic acid (ZA) and/or strontium-89 (Sr-89). Combined therapy with ZA and Sr-89 is of clinical significance for patients with NSCLC with asymptomatic BMs.</description><identifier>ISSN: 1525-7304</identifier><identifier>EISSN: 1938-0690</identifier><identifier>DOI: 10.1016/j.cllc.2012.09.001</identifier><identifier>PMID: 23103352</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Bone Density Conservation Agents - therapeutic use ; Bone metastases ; Bone Neoplasms - drug therapy ; Bone Neoplasms - mortality ; Bone Neoplasms - secondary ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - secondary ; Diphosphonates - therapeutic use ; Double-Blind Method ; Female ; Fractures, Bone - prevention & control ; Hematology, Oncology and Palliative Medicine ; Humans ; Hypercalcemia - prevention & control ; Imidazoles - therapeutic use ; Kaplan-Meier Estimate ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Non–small-cell lung cancer ; Paraneoplastic Syndromes - prevention & control ; Pulmonary/Respiratory ; Skeletal-related event ; Spinal Cord Compression - prevention & control ; Strontium - therapeutic use ; Strontium-89 ; Zoledronic acid</subject><ispartof>Clinical lung cancer, 2013-05, Vol.14 (3), p.254-260</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3</citedby><cites>FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23103352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Yaopeng</creatorcontrib><creatorcontrib>Tao, Hao</creatorcontrib><creatorcontrib>Yu, Xuyi</creatorcontrib><creatorcontrib>Wang, Zhan</creatorcontrib><creatorcontrib>Wang, Mingzhao</creatorcontrib><title>Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non–Small-Cell Lung Cancer</title><title>Clinical lung cancer</title><addtitle>Clin Lung Cancer</addtitle><description>Micro-Abstract Patients with non–small-cell lung cancer (NSCLC) often have bone metastases (BMs) in the late stage of disease. One hundred eighty patients with NSCLC were selected and treated with zoledronic acid (ZA) and/or strontium-89 (Sr-89). Combined therapy with ZA and Sr-89 is of clinical significance for patients with NSCLC with asymptomatic BMs.</description><subject>Adult</subject><subject>Aged</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone metastases</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Diphosphonates - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Fractures, Bone - prevention & control</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Hypercalcemia - prevention & control</subject><subject>Imidazoles - therapeutic use</subject><subject>Kaplan-Meier Estimate</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Non–small-cell lung cancer</subject><subject>Paraneoplastic Syndromes - prevention & control</subject><subject>Pulmonary/Respiratory</subject><subject>Skeletal-related event</subject><subject>Spinal Cord Compression - prevention & control</subject><subject>Strontium - therapeutic use</subject><subject>Strontium-89</subject><subject>Zoledronic acid</subject><issn>1525-7304</issn><issn>1938-0690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9UsuqFDEQbUTxXq_-gAvJ0k23laS7pwMijI0vGB8wiuAmZPK4ZkwnY5IWZufWtX_ol5hmRhcuJIEUlXNOJXWqqu5jaDDg_tG-kc7JhgAmDbAGAN-oLjGjQw09g5sl7khXryi0F9WdlPYApKeY3K4uCMVAaUcuqx-js95K4dDWXntrSuilRsGgT8FpFUO5RGtpFRJeoW0uiWznqR4Ysh69E9lqnxP6aPNntE7H6ZDDVJISPQ1eo9c6i1S2TsjEMKE3wf_6_nM7CefqUTuHNrO_RuNSMt6tbhnhkr53Pq-qD8-fvR9f1pu3L16N600tW4xzbSgwNvSdaDswlKgdbamU3WroiQEhwaidIQNmQyuIYF1B4Z1UK6PKogIrelU9POkeYvg665T5ZJMsjxFehzlxTElHCRvoqkDJCSpjSClqww_RTiIeOQa-WMD3fLGALxZwYLxYUEgPzvrzbtLqL-VPzwvg8Qmgyy-_WR15kqWLUisbtcxcBft__Sf_0OXZwi_6qNM-zNGX_nHMU-Hw7TIEywxgUthsIPQ3gPGuKw</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Wang, Yaopeng</creator><creator>Tao, Hao</creator><creator>Yu, Xuyi</creator><creator>Wang, Zhan</creator><creator>Wang, Mingzhao</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130501</creationdate><title>Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non–Small-Cell Lung Cancer</title><author>Wang, Yaopeng ; Tao, Hao ; Yu, Xuyi ; Wang, Zhan ; Wang, Mingzhao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone metastases</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Diphosphonates - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Fractures, Bone - prevention & control</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Hypercalcemia - prevention & control</topic><topic>Imidazoles - therapeutic use</topic><topic>Kaplan-Meier Estimate</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Non–small-cell lung cancer</topic><topic>Paraneoplastic Syndromes - prevention & control</topic><topic>Pulmonary/Respiratory</topic><topic>Skeletal-related event</topic><topic>Spinal Cord Compression - prevention & control</topic><topic>Strontium - therapeutic use</topic><topic>Strontium-89</topic><topic>Zoledronic acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yaopeng</creatorcontrib><creatorcontrib>Tao, Hao</creatorcontrib><creatorcontrib>Yu, Xuyi</creatorcontrib><creatorcontrib>Wang, Zhan</creatorcontrib><creatorcontrib>Wang, Mingzhao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lung cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yaopeng</au><au>Tao, Hao</au><au>Yu, Xuyi</au><au>Wang, Zhan</au><au>Wang, Mingzhao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non–Small-Cell Lung Cancer</atitle><jtitle>Clinical lung cancer</jtitle><addtitle>Clin Lung Cancer</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>14</volume><issue>3</issue><spage>254</spage><epage>260</epage><pages>254-260</pages><issn>1525-7304</issn><eissn>1938-0690</eissn><abstract>Micro-Abstract Patients with non–small-cell lung cancer (NSCLC) often have bone metastases (BMs) in the late stage of disease. One hundred eighty patients with NSCLC were selected and treated with zoledronic acid (ZA) and/or strontium-89 (Sr-89). Combined therapy with ZA and Sr-89 is of clinical significance for patients with NSCLC with asymptomatic BMs.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23103352</pmid><doi>10.1016/j.cllc.2012.09.001</doi><tpages>7</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 1525-7304
ispartof	Clinical lung cancer, 2013-05, Vol.14 (3), p.254-260
issn	1525-7304 1938-0690
language	eng
recordid	cdi_proquest_miscellaneous_1325329837
source	ScienceDirect Freedom Collection 2022-2024
subjects	Adult Aged Bone Density Conservation Agents - therapeutic use Bone metastases Bone Neoplasms - drug therapy Bone Neoplasms - mortality Bone Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Diphosphonates - therapeutic use Double-Blind Method Female Fractures, Bone - prevention & control Hematology, Oncology and Palliative Medicine Humans Hypercalcemia - prevention & control Imidazoles - therapeutic use Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Non–small-cell lung cancer Paraneoplastic Syndromes - prevention & control Pulmonary/Respiratory Skeletal-related event Spinal Cord Compression - prevention & control Strontium - therapeutic use Strontium-89 Zoledronic acid
title	Clinical Significance of Zoledronic Acid and Strontium-89 in Patients With Asymptomatic Bone Metastases from Non–Small-Cell Lung Cancer
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A28%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Significance%20of%20Zoledronic%20Acid%20and%20Strontium-89%20in%20Patients%20With%20Asymptomatic%20Bone%20Metastases%20from%20Non%E2%80%93Small-Cell%20Lung%20Cancer&rft.jtitle=Clinical%20lung%20cancer&rft.au=Wang,%20Yaopeng&rft.date=2013-05-01&rft.volume=14&rft.issue=3&rft.spage=254&rft.epage=260&rft.pages=254-260&rft.issn=1525-7304&rft.eissn=1938-0690&rft_id=info:doi/10.1016/j.cllc.2012.09.001&rft_dat=%3Cproquest_cross%3E1325329837%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-f3099865a450f32db343cc57862f0ac0fdbf281984a2a954501bcd7fdfdf3a1d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1325329837&rft_id=info:pmid/23103352&rfr_iscdi=true